Paradigm Biopharmaceuticals Ltd
ASX:PAR
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Price:
0.275 AUD
-3.51%
Market Closed
Updated:
May 2, 2024
Paradigm Biopharmaceuticals Ltd
Cash from Financing Activities
|
Paradigm Biopharmaceuticals Ltd
Cash from Financing Activities Peer Comparison
Comparables:
IMM
MSB
CSL
CUV
TLX
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Paradigm Biopharmaceuticals Ltd
ASX:PAR
|
Cash from Financing Activities
AU$28.5m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Immutep Ltd
ASX:IMM
|
Cash from Financing Activities
AU$76m
|
CAGR 3-Years
15%
|
CAGR 5-Years
29%
|
CAGR 10-Years
19%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Cash from Financing Activities
$67.8m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Cash from Financing Activities
-$1.6B
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-8%
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Cash from Financing Activities
-AU$2.7m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Cash from Financing Activities
AU$10.2m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Paradigm Biopharmaceuticals Ltd's Cash from Financing Activities?
Cash from Financing Activities
28.5m
AUD
28.5m
AUD
Based on the financial report for Dec 31, 2023, Paradigm Biopharmaceuticals Ltd's Cash from Financing Activities amounts to 28.5m AUD.
What is Paradigm Biopharmaceuticals Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
22%
22%
Over the last year, the Cash from Financing Activities growth was -54%. The average annual Cash from Financing Activities growth rates for Paradigm Biopharmaceuticals Ltd have been -7% over the past three years , 22% over the past five years .
You don't have any saved screeners yet
